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Abstract
Background: Our laboratory has shown that a locus on the SHR Y chromosome increases blood
pressure (BP) in the SHR rat and in WKY rats with the SHR Y chromosome (SHR/y rat). A
candidate for this Y chromosome hypertension locus is Sry, a gene that encodes a transcription
factor responsible for testes determination. The SHR Y chromosome has six divergent Sry loci. The
following study examined if exogenous Sry1 or Sry2 delivered to the kidney would elevate renal
tyrosine hydroxylase, renal catecholamines, plasma catecholamines and telemetered BP over a 28
day period. We delivered 50 μg of either the expression construct Sry1/pcDNA 3.1, Sry2/pcDNA
3.1, or control vector into the medulla of the left kidney of normotensive WKY rats by
electroporation. Weekly air stress was performed to determine BP responsiveness. Separate
groups of animals were tested for renal function and plasma hormone patterns and pharmacological
intervention using alpha adrenergic receptor blockade. Pre-surgery baseline and weekly blood
samples were taken from Sry1  electroporated and control vector males for plasma renin,
aldosterone, and corticosterone. BP was measured by telemetry and tyrosine hydroxylase and
catecholamines by HPLC with electrochemical detection.
Results: In the animals receiving the Sry1 plasmid there were significant increases after 21 days in
resting plasma norepinephrine (NE, 27%) and renal tyrosine hydroxylase content (41%, p < .05)
compared to controls. BP was higher in animals electroporated with Sry1 (143 mmHg, p < .05)
compared to controls (125 mmHg) between 2–4 weeks. Also the pressor response to air stress
was significantly elevated in males electroporated with Sry1 (41 mmHg) compared to controls (28
mmHg, p < .001). Sry2 did not elevate BP or SNS indices and further tests were not done. The
hormone profiles for plasma renin, aldosterone, and corticosterone between electroporated Sry1
and control vector males showed no significant differences over the 28 day period. Alpha
adrenergic receptor blockade prevented the air stress pressor response in both strains. Urinary
dopamine significantly increased after 7 days post Sry electroporation.
Conclusion: These results are consistent with a role for Sry1 in increasing BP by directly or
indirectly activating renal sympathetic nervous system activity.
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Background
We have shown previously that there is a locus on the SHR
Y chromosome that increased blood pressure (BP) in an
additive manner by 20–25 mmHg and that The Y chromo-
some Sry locus increased tyrosine hydroxylase promoter
activity [1-4] and increased several indices of sympathetic
nervous system (SNS) activity [5]. We demonstrated that
renal norepinephrine (NE) turnover rate is higher by
100% and renal NE content is 44% higher in males with
the SHR Y chromosome [6]. Studies in our lab indicate
that a candidate gene for this SNS and BP effect is the Sry
gene complex on the rat Y chromosome. The Sry protein
is a transcription factor that has been shown to be the tes-
tis determining factor in mice and humans [7], although
Sry expression has been reported in adult testis, brain,
adrenal gland and in additional tissues that have BP rele-
vance in humans and rodents [8-11]. The Sry protein has
potential target loci not involved in testis determination.
We have demonstrated that one of the six copies of the Sry
gene complex, Sry1, increased tyrosine hydroxylase (Th)
promoter activity in transfected PC12 cells [7]. Th is the
rate limiting enzyme in the catecholamine biosynthesis
pathway; thus regulation of Th by Sry1 is a potential path-
way for an Sry locus to affect BP. There were two compo-
nents to the activation effects of Sry1 on the Th promoter,
one is an indirect effect through an AP-1 transcription fac-
tor binding site. Consistent with this result is the observa-
tion that Sry binding sites have been identified in Fra-1
and Fra-2, both components of the AP-1 transcription fac-
tor [12]. Recently, we examined the impact of Sry1 expres-
sion in the adrenal medulla., Sry1 exogenously delivered
to the adrenal medulla by electroporation increased adre-
nal Th activity, plasma NE and BP compared to vector
controls [1]. In additional support of an Sry effect on Th,
Dewing et al. has shown that Sry is expressed in the sub-
stantia nigra of both the mouse and rat brain and down-
regulation of Sry by antisense Sry in the substantia nigra
produced a decrease in Th neurons and altered motor
behavior [13].
We have also reported that Sry transcripts are present in
the kidney of adult male rats [14]. Since the kidney is
involved in several different mechanisms of hypertension,
and based on our previous observations of SNS involve-
ment in hypertension, we developed the following
hypothesis: delivery of exogenous Sry  to the kidney
medulla of a normotensive WKY rat will increase BP
through effects on renal Th activity, and elevated SNS
indices.
The electroporation technique of gene delivery was devel-
oped primarily for use in cell culture, but it has also been
successfully used in various tissues in the whole animal.
For instance, delivery of exogenous genes produced phys-
iological responses in nephrectomized rats, showing that
rat erythropoietin injection corrected anemia [15], and
raised hematocrit from 47% to 80% [16]. Tsuji et al exam-
ined the efficiency of intrarenal injection of DNA fol-
lowed by in vivo electroporation and found that
mesangial cells were transfected and no histological dam-
age was observed [17].
Methods
Adult WKY males (n = 82) were used in the following
studies. The rationale for using WKY males is that they
have normal blood pressure and if the exogenous Sry
delivered would result in a BP elevation it would be better
observed in the normotensive animal rather in one with
borderline or fully developed hypertension. All animal
protocols were approved by the Institutional Animal Care
and Use Committee of the University of Akron. The exper-
imental design explored four questions: 1. Does delivery
of exogenous Sry1, Sry2 or control vector alter renal NE
and BP?, 2. Does delivery of exogenous Sry1, Sry2 or con-
trol vector alter renal function or morphology?, 3. Does
delivery of exogenous Sry1 or control vector alter plasma
hormones involved in BP control-aldosterone, plasma
renin activity and corticosterone?, and 4. Is the BP pressor
effect blocked by an alpha adrenergic blocker?
The objective of the first experiment was to test the
hypothesis that exogenous Sry1  would elevate BP, but
Sry2 would not. Sry1, Sry2 or control vector was delivered
to the kidney medulla of normotensive WKY rats (n = 6/
group). Animals were implanted with telemetry probes
(Data Sciences) in the abdominal aorta just above the
renal artery as previously described (see below). The Sry1
expression construct, Sry1/pcDNA3.1(-), which includes
the complete SHR Sry1 coding sequence (bp#11-520 of
GenBank accession number, AF274872), as described pre-
viously.[7] The full length SHR Sry2  coding sequence,
from an XbaI/Not l genomic fragment, was cloned into
pcDNA3.1(-), to produce the expression construct, Sry2/
pcDNA3.1(-) with the Sry2 coding region (bp#246-716 of
GenBank accession number, AY157670).
The objective of the second experiment was to test the
hypothesis that electroporation of Sry1 or empty vector to
the kidney did not alter renal excretory function. Either
empty vector or Sry1/pcDNA3.1(-)was injected into the
left kidney of WKY rats (n = 6/group) following the same
procedure as experiment 1. Twenty four hour urine and
blood samples were analyzed for creatinine clearance,
BUN and urinary protein, catecholamines and sodium,
and histology to verify that the electroporation procedure
did not cause renal damage. The same electroporation
protocol was followed as in the first experiment. Adult
male WKY were injected with Sry1/pcDNA3.1(-) (n = 6)
or empty vector (n = 6) and electroporated to examine the
tissue for damage. A control group of WKY kidneys (n = 6)BMC Physiology 2009, 9:10 http://www.biomedcentral.com/1472-6793/9/10
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that was not injected or electroporated was also examined
for comparison.
The objective of the third experiment was to test the
hypothesis that electroporation of Sry1 or empty vector
did not alter plasma hormones (renin, aldosterone, and
corticosterone) that potentially could be involved with
high BP. The same Sry1 or control vector delivery protocol
as above was used on WKY males (n = 4/group). Blood
was collected weekly for 4 weeks before and after treat-
ment under pentothal anesthesia (50 mg/kg, ip) and spun
down for plasma separation, frozen at -80C and analyzed
by RIA: plasma renin activity (Diasorin; Stillwater, MN),
plasma corticosterone and aldosterone (Diagnostic Sys-
tems Laboratories, Inc. Webster, TX).
The objective of the 4th experiment was to examine stress
induced telemetered BP with alpha adrenergic blockade
(prazosin 0.5 mg/kg, ip.) and urinary catecholamines
after Sry1 or control vector delivery to the kidney. The
same Sry1 or empty vector delivery protocol as above was
used on WKY males (n = 4/group).
Electroporation
For all of the electroporation procedures the following
protocol was used. Each tissue has different optimal elec-
troporation parameters that have been described for gene
delivery [18]. Based on previous research and our own
pilot tests we performed electroporation in a pulsatile
fashion immediately after DNA injection. Either 50 μg of
Sry1/pcDNA3.1(-), or 50 μg of control pcDNA3.1(-) vec-
tor without Sry1 sequences was injected into the left kid-
ney medulla of 6 WKY adult male rats using pentothal as
an anesthetic (50 mg/kg, ip). Sry1, or control vector, was
delivered by injection (28 g needle) followed by electro-
poration into the kidney medulla. A mark was placed on
the needle to insure proper depth to the medulla and two
injections were administered one to the upper quadrant
and one to the lower quadrant of the kidney. A drop of
glycerol was placed on the injection site before injection
to prevent fluid backflow. Tweezer electrodes (BTX Tweez-
ertrodes Model #522) connected to an electrostimulator
(ElectroCellManipulator™, ECM® 830, BTX, a division of
Genentronics), were placed on opposite sides of the kid-
ney and 20 bipolar electrical pulses administered, 200
volts, each lasting 20 msec, at 1000 Hz after both injec-
tions. After stimulation the incision was closed and the
animal allowed to recover. For the Sry2 studies the same
procedure was followed but 50 μg of Sry2/pcDNA3.1(-),
or 50 μg of control pcDNA3.1(-) vector without Sry2
sequences was injected into the left kidney medulla of
WKY adult male rats(n = 6/group). These animals were
also implanted with telemetry receivers and monitored as
described below.
In order to verify that this procedure delivered Sry1 to the
kidney, two WKY females were electroporated with Sry1
delivered to the kidney using the same protocol as
described above. The plasmid-Sry1, cannot be distin-
guished from endogenous Sry, therefore the use of females
for verification. Total DNA was screened for the presence
of  Sry1  by gel-based PCR using the primer set M1-P1
which amplify from the HMG box of all Sry loci.
Blood Pressure, Heart Rate and Alpha Blocker Studies
Blood pressure and heart rate were measured continu-
ously in conscious animals by telemetry and plotted
weekly before and after electroporation (Data Sciences)
[5]. For the stress procedures, air stress was performed by
using compressed air which traveled through Tygon tub-
ing (1/4 × 1/16 inch) connected to a Pasteur pipette and
the air was directed into the face of the rat at a pressure of
10 psi for 30 seconds. During this time three 10 second
pressure readings were taken and the highest of the three
used for the air stress results. The air stress was performed
on all the rats before Sry1or Sry2 or empty vector was
delivered into the left kidneys for the baseline values. After
Sry1 or Sry2 or empty vector delivery, air stresses were
done at days 8, 15, and 22. In another group of adult WKY
males Sry1 (n = 4) or empty vector control (n = 4) was
delivered to the kidney in the same manner as above. Day
22 post Sry or EV delivery 0.5 mg/kg prazosin was injected
(ip) and after 30 min an air stress test performed (30 sec).
Catecholamine and Tyrosine Hydroxylase Analysis
Levels of renal Th and catecholamines were measured 21
days after electroporation. Th and catecholamines were
measured by HPLC with electrochemical detection as we
previously reported [1] (Waters 2465, Milford, MA). For
Th analysis kidneys were homogenized in 500 μl of 0.25
M sucrose. The homogenate (100 μl) was added to both a
blank tube and a reaction tube. The chemical reaction was
based on procedures developed by Nagatsu [19] and
modified by Hooper et al [20] and Kumai et al [21] fol-
lowed by extraction using the same method as for cate-
cholamines.
Urine Collection and Analysis
For the urine collection studies rats were placed into met-
abolic cages for 24 hour urine collection during baseline
before plasmid delivery and during various days post plas-
mid delivery. They were given Pro-lab 3000 food and
water ad libitum. Mineral oil was placed into the urine
collection cup to prevent urine evaporation over the col-
lection period for sodium and creatinine measures. For
the catecholamine collections 1 ml of 6N HCl and min-
eral oil was added to the collection cup. The 24 hour
urines were tested for total protein by sulfosalycidic acid
turbidity method and creatinine clearance (Thermo Elec-
tron; Pittsburgh, PA) [22] and sodium by flame photom-BMC Physiology 2009, 9:10 http://www.biomedcentral.com/1472-6793/9/10
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etry. Urinary catecholamines (24 hr) were performed at
baseline, stress, 7,14, 21, and 28 days post electropora-
tion. Using a separate group of animals (Vector control, n
= 8 and Sry1, n = 8) the same procedure was followed as
in experiment 2 and urine was collected at 7, 14 and 21
days for sodium and catecholamines. At day 14 and 21 a
non-selective dopamine blocker, metoclopramine was
injected (0.5 mg/kg, ip) to each animal and 24 hour urine
collected.
Kidney Morphology
In the third study the electroporated left kidney was
removed after 21 days, stored in 10% buffered formalin,
dehydrated in a tissue processor (Tissue-Tek, Miles Inc.,
Elkhart, IN) and paraffin embedded (Paraplast Plus,
Fisher Sci). Sections were cut at 6 μ and stained with
hemotoxylin and eosin (Richard Allan Scientific, Kalama-
zoo, MI) to assess the tissue for potential gene delivery-
electroporation injury. Glomeruli and tubules were
scored blindly by 3 individuals for pathological changes
[23].
Statistical Analysis
BP, urinary Na, hormones, and urinary catecholamines
were tested with 2-way ANOVA(group and time) with
repeated measures. Th, creatinine, BUN, protein and cate-
cholamine renal content were analyzed using t-tests and;
means and standard error of the means are reported; sig-
nificance was assumed if p < .05.
Results
Figure 1A shows BP before and after delivery of either
Sry1, or the empty control vector to the kidney. There was
a significant increase in BP after Sry1 delivery compared to
control vector at days 7,14, 21: 143,142,141 vs.
127,125,127 mmHg, respectively (p < .05) and BP was
normalized after 28 days. When Sry2 was delivered to the
kidney in the same manner there was not a BP effect (Fig-
ure 1B). Figure 2A shows the significant and consistent
elevation in pressor response to air stress in the Sry1 group
(41 mmHg) compared to controls (28 mmHg) at days 8
and 22. The drop in pressor response that occurred at day
15 is unexplained. When Sry2 was delivered to the kidney
in the same way there was no difference in BP response to
air stress between Sry2 and controls (Figure 2B). Figure 2C
shows that the pressor response to air stress was com-
pletely blocked in both Sry1 and control animals treated
animals with prazosin. The BP responses cannot be
explained by heart rate which were the same between
stressed Sry1(333 +/- 32) and control groups (331 +/- 7).
Figure 3 shows that 21 days after Sry1 delivery to the kid-
ney, Th was significantly increased compared to the vector
control (21 vs. 15 fmol/min/mg, p < .05), however Sry2
did not produce any significant Th difference compared to
controls. With regard to kidney catecholamine content
there were no significant differences in NE or dopamine
content between animals delivered vector or Sry1 or Sry2
DNA measured at 21 days. Creatinine clearance, urinary
protein, sodium and BUN were not significantly different
between groups and were within normal range, suggesting
that the electroporation procedure did not damage the
kidney or alter renal function (Table 1). Urinary Na was
also measured at 7, 14 and 28 days after electroporation
besides the 21 value reported in Table 1 and was not sig-
nificantly different between groups (Control vector vs.
Sry1: 7 day = 0.11 vs. 0.13 mmol/hr/100 gms, 14 day =
0.15 vs. 0.14, 28 day = 0.18 vs. 0.17). Plasma NE was sig-
nificantly elevated (57%) 21 days after Sry1 delivery com-
pared to vector control (Table 1). Figure 4 shows the pre-
surgery baseline and weekly plasma levels of renin, aldos-
terone, and corticosterone for the Sry1 and control vector
groups. There were no significant differences between
treatment groups for each plasma hormone at all time
periods sampled. Figure 5 shows that 7 days after Sry1
delivery urinary dopamine and NE were significantly ele-
vated but returned to baseline levels with time (two-way
ANOVA, strain difference, F = 5.1, p < .05 for dopamine
and F = 4.6, p < .05 for NE).
After 21–28 days all catecholamine levels were not differ-
ent from baseline values.
Histological examination of successive sections through
the kidney medulla did not show any morphological dif-
ferences between non-electroporated controls, control
vector, or Sry1 delivered (Figure 6).
The females that had Sry1 electroporated in the left kidney
were positive for Sry in the left kidney after 8 days, they
were negative in the right kidney and positive in the liver.
After 21 days the left and right kidney were negative but
the liver remained positive.
Discussion
Since the Y chromosome is inherited as a unit, determin-
ing which gene or genes are responsible for the hyperten-
sive effect of the SHR Y chromosome requires the testing
of potential Y chromosome hypertension genes. We have
proposed  Sry1  as a potential candidate gene for the Y
chromosome hypertension. One step in this process is
demonstrating that Sry1 can affect BP [24], but there are
six Sry loci on the SHR Y chromosome [11]. Whether the
effects of the hypertensive Y chromosome are unique to a
single locus, Sry1, or a combination of more than one of
the Sry loci is not known [11]. In this investigation we
have electroporated Sry1 and Sry2 into the normotensive
WKY kidney. Sry1 has been demonstrated to have a BP
effect when exogenously expressed in the adrenal [1]. Sry2
is the most divergent of the 6 Sry loci [11] and thus the
most likely to have a different effect.BMC Physiology 2009, 9:10 http://www.biomedcentral.com/1472-6793/9/10
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A. Telemetered systolic blood pressure (SBP) was significantly elevated after Sry1 delivery to the kidney as compared to con- trol vector (means, +/- s.e.m., ** = p < .01, n = 6/group) Figure 1
A. Telemetered systolic blood pressure (SBP) was significantly elevated after Sry1 delivery to the kidney as 
compared to control vector (means, +/- s.e.m., ** = p < .01, n = 6/group). B. Telemetered systolic blood pressure 
(SBP) was not significantly elevated after Sry2 delivery to the kidney as compared to vector controls (means, +/- s.e.m., no sig-
nificant differences).
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A. Change in telemetered systolic blood pressure (SBP) from baseline during 30 sec. air stress in Sry1 and control vector  groups (means, +/- s.e.m., 2-way ANOVA, ** = p < .01, n = 6/group) Figure 2
A. Change in telemetered systolic blood pressure (SBP) from baseline during 30 sec. air stress in Sry1 and con-
trol vector groups (means, +/- s.e.m., 2-way ANOVA, ** = p < .01, n = 6/group). B. Change in telemetered systolic 
blood pressure (SBP) from baseline during 30 sec. air stress in Sry2 and control vector groups (means, +/- s.e.m., n.s., n = 6/
group). C. Alpha blockade with prazosin (0.5 mg/kg, ip) effectively blocked the stress induced BP rise, means, +/- s.e.m., < .05.
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Our main finding was that Sry1 delivered to the kidney
resulted in elevated BP while Sry2 did not. The time scale
of the BP response is consistent with the responses of
other genes delivered by electroporation which is about
7–21 days after electroporation for peak effect [1,24]. The
lack of a BP increase with control vector or Sry2 demon-
strates that the BP increase was due specifically to the
addition of Sry1 sequences, not to electroporation itself or
an effect of the plasmid sequences. The divergence of Sry2
has apparently changed the binding or transcriptional
activation characteristics of the Sry2 protein. The differ-
ence between Sry1 and Sry2 has to be the result of differ-
ences inherent in the proteins and not a difference in
transcription of the Sry1 and Sry2 plasmid since both have
the same promoter and plasmid. Whether or not the other
Sry loci have hypertensive potential like Sry1 must to be
tested individually as each locus has unique differences.
The electroporation of exogenous Sry1 DNA in the kidney
of WKY rats increased BP by 15 mmHg, comparable to the
20 mmHg effect produced through breeding by replacing
the entire SHR or WKY Y chromosome. We saw a similar
BP increase when Sry1 was electroporated into the adrenal
gland [1]. These increases are larger or equal to the effects
of BP QTLs in other rat models of hypertension [25],
which are potentially composed of multiple genetic BP
components. Our results confirm the potential physiolog-
ical influence of Sry1 on BP.
The demonstration of an in vivo effect of Sry1 in the kidney
is of physiological consequence only if Sry1 is normally
expressed in the SHR kidney. We have previously demon-
strated the presence of Sry transcripts in the kidney with-
out regard to locus. Although all six Sry loci are expressed
in the 15 week old adult male testis, the adrenal and testis
have a different expression pattern of the Sry; Sry2 is the
primary transcript in the adrenal but significantly reduced
in the testis [11]. The expression pattern of Sry1 or the
other copies in the kidney or at other developmental
times in the adrenal has not yet been reported.
Based on two of our previous studies, the SNS was indi-
cated as involved in the elevated BP mechanism: 1) in
PC12 cells [7]Sry1 increased Th promoter activity by 50%
compared to control vector, and 2) we found a 49%
increase in Th in the rat adrenal medulla [1] after Sry1
electroporation and similar effects on BP. We have not yet
electroporated both tissues (adrenal gland and kidney) in
Renal tyrosine hydroxylase activity (measured as L-DOPA formed per minute per mg tissue, fm/min/mg) in kidney 21 days after  plasmid delivery to Sry1 (n = 6), Sry2 (n = 4) and control vector (n = 6) (means, +/- s.e.m., ** = p < .01) Figure 3
Renal tyrosine hydroxylase activity (measured as L-DOPA formed per minute per mg tissue, fm/min/mg) in 
kidney 21 days after plasmid delivery to Sry1 (n = 6), Sry2 (n = 4) and control vector (n = 6) (means, +/- s.e.m., 
** = p < .01).
0
5
10
15
20
25
Control
Vector
Sry2
*
  Sry1
R
e
n
a
l
 
T
y
r
o
s
i
n
e
 
H
y
d
r
o
x
y
l
a
s
e
 
 
 
 
 
 
 
 
(
f
m
o
l
/
m
i
n
/
m
g
)
*BMC Physiology 2009, 9:10 http://www.biomedcentral.com/1472-6793/9/10
Page 8 of 13
(page number not for citation purposes)
Hormone profiles over time in control (solid circles, n = 4) and Sry1 (open circles, n = 4) animals for A. plasma renin activity,  B. plasma aldosterone, and C. plasma corticosterone (means, +/- s.e.m., no significant differences) Figure 4
Hormone profiles over time in control (solid circles, n = 4) and Sry1 (open circles, n = 4) animals for A. plasma 
renin activity, B. plasma aldosterone, and C. plasma corticosterone (means, +/- s.e.m., no significant differ-
ences).
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Urinary catecholamines (A. norepinephrine, B. dopamine) in animals from experiment 4 from across time in Sry1 or control  vector, n = 6–7/group), means, +/- s.e.m.,*= p < .05, ** = p < .01 compared to control vector Figure 5
Urinary catecholamines (A. norepinephrine, B. dopamine) in animals from experiment 4 from across time in 
Sry1 or control vector, n = 6–7/group), means, +/- s.e.m.,*= p < .05, ** = p < .01 compared to control vector.
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a single animal to see if there is an additive effect. The
demonstration of a BP increase with electroporation of
Sry1 into either the kidney or adrenal gland indicates that
Sry1 could have its effect in either organ or in both. The
lack of effect of Sry2 on BP or SNS indices further supports
our hypothesis that it is specifically Sry1 that produces the
elevated BP. This is not to preclude other phenotypic
effects of Sry2. A question that arise is the possibility that
by injecting Sry1 into the upper and lower pole of the kid-
ney, some Sry1 from the upper site may overflow into the
left adrenal gland and influence the production of adrenal
NE which could then increase plasma catecholamines and
increase BP. To check this possibility we measured left
adrenal NE and E content in the animals from the hor-
mone study and found there were no significant adrenal
gland differences in NE and epinephrine content between
renal delivered Sry1 or control vector (data not shown).
This does not exclude the possibility that some Sry1 plas-
mid may spill over to the circulation and increase Sry1 lev-
els in other tissues. In females who lack the Sry gene, we
can identify the Sry1 plasmid delivered. Detection of it in
the kidney shows that it was present after 8 days, but also
some via the circulation was found in the liver at 8 and 21
days. This suggests that it could be transported to other tis-
sues and be expressed. Further studies are documenting
tissue distribution and cellular localization.
With regard to the general concept of the involvement of
the renal SNS and hypertension, it has been shown that
increased renal sympathetic nerve activity has diverse
functions in regulating the intrarenal effectors, such as the
tubules, the blood vessels, and the juxtaglomerular granu-
lar cells. In a review of renal neural regulation by Di Bona
[26], the SNS is shown to coordinate the circulatory, filtra-
tion, reabsorptive, excretory, and renin secretory contribu-
tions in the kidney. The SNS appears to be able to affect
vascular, tubule and JG cell function individually, as well
as in concert [26]. The concept of functionally specific
renal sympathetic nerve fibers allows more finite control
of renal function. In addition, the idea that Sry may be
functionally active in the kidney is one more example of
how the SNS can differentially provide fine tuning of
organ function. In the SHR model of hypertension the
SNS has been shown to play an important role in the
development of BP control and in hypertension [27]. The
SNS is the primary mediator of acute changes in BP and
also chronically contributes to BP regulation.
The evidence supporting an Sry1-SNS interaction is
mounting. SHR/y males have more renal NE content and
a 67% increase in renal NE turnover compared to WKY
males, indicating greater SNS activation attributed to the
SHR Y chromosome [6]. In fact, the kidney NE turnover
rate in the SHR/y males was the same as in SHR males,
suggesting that the catecholamine pathway, at least in the
kidney, is significantly influenced by the Y chromosome
[5]. Also the pressor response to air stress appears to be
mediated by the SNS and was on the average, 15 mmHg
higher in the presence of exogenous Sry1 compared to
control vector. Alpha adrenergic receptor blockade elimi-
nated the pressor response in both strains suggesting that
the pressor response was due to SNS activated vasocon-
striction. Consistent with the specificity of an effect for
Sry1was the lack of SNS responses after administration of
Sry2.
In addition, we expected to observe that Sry1 would cause
a renal increase of the rate limiting enzyme for NE synthe-
sis, Th, to be elevated. Indeed renal Th was elevated after
Sry1 but not after Sry2 delivery. Elevated Th and/or cate-
cholamine levels are established physiological characteris-
tics of many hypertensive animal models and human
studies [26-36]. We have shown that the Y chromosome
from a SHR male when backcrossed to a normotensive
WKY female increased SNS indices [4] and maintained an
increase in BP of about 20 mmHg even after 11 genera-
tions of backcrossing sons to WKY females in the SHR/y
strain [3].
What are the pathways whereby Sry can lead to elevated
Th? One possibility is that the Sry protein travels to the
celiac ganglia where the cell bodies that contain Th are
located. Recently we have verified that endogenous Sry is
present in celiac ganglia. Based upon our in vitro studies,
Table 1: Urine and Plasma Profile
Urinary Protein 
(mg/dl)
BUN (mg/dl) Urinary 
Creatinine 
Clearance 
(ml/min/gm bw)
Urinary Na 
(mmol/hr/100 
gms)
Urinary Na With 
Dopamine 
Blockade
(mmol/hr/100 
gms)
Plasma NE 
(pg/ml)
Plasma Epi 
(pg/ml)
Control Vector
(n = 6–7)
46
+/- 15
13.6
+/- 0.8
0.65
+/- .07
0.17
+/- .01
0.11
+/- .013
375
+/- 70
95
+/- 10
Sry1
(n = 6–7)
53
+/- 15
15.4
+/- 0.2
0.63
+/- .09
0.17
+/- .01
0.15 *
+/- .011
590 *
+/- 20
80
+/- 5
Means, +/- s.e.m., * = p < .05 compared to control vector. Data collected at 21 days.BMC Physiology 2009, 9:10 http://www.biomedcentral.com/1472-6793/9/10
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Sry1 promotes Th transcription [7]. Th may travel down
the sympathetic nerves to the kidney residing in the nerve
terminal and some Th may be also released into the syn-
apse. We do know that in whole kidney there is Th activ-
ity, and when blood is removed from the kidney by saline
perfusion, the total Th content does not change, so the Th
measured is content from the kidney tissue and not the
blood. Th may also be synthesized or released from the
kidney itself. For example, in cultured rat mesangial cells,
both Th and NE are present suggesting that the synthetic
materials are present for the catecholamine pathway [37].
We assume this is also true in the whole animal, i.e. renal
synthesis of NE.
Besides elevated renal Th we expected to observe increases
in other SNS indicators: renal NE content and urinary cat-
echolamines in the Sry1 treated animals. Although, renal
Th at 21 days and urinary catecholamines (7 days) were
elevated, renal NE content only showed an elevated non-
significant trend. The renal NE content reflects a chronic
measure of total stores of NE over time. Since renal Th was
elevated we expected to observe renal NE content to be
elevated. It may be that since the renal content is so high
(80–90,000 pg/gm in a 1 gm kidney) that the Sry1
induced differences are small enough they are not
reflected in total content differences. Multiple and com-
plex mechanisms contribute to Th activity and catecho-
lamine synthesis during SNS activation. Short term
mechanisms include feedback inhibition and enzyme
phosphorylation. Long term mechanisms include changes
in Th synthesis [34]. There appears to be an uncoupling of
the tissue NE content, activity of Th and the release of NE.
Two storage pools of NE exist in both the SNS nerve ter-
minals and in the adrenal medulla: a small readily releas-
able pool of newly synthesized NE and a large reserve
pool in long term storage [30]. For example, studies in rats
show a 35% reduction in Th activity at all ages studied (5,
12, 22 weeks) while plasma NE was 3–4× higher in SHR
compared to WKY rats [36]. Therefore, NE storage, cyto-
plasmic pools and plasma levels need not be in a linear
direct relationship.
The counter balance to renal SNS-NE effects and sodium
retention is the effect of renal dopamine as a natriuretic
factor. Renal dopamine does not derive from the SNS or
the typical neuronal NE pathway but instead proximal
tubule cells use circulating or filtered L-DOPA as a source
of dopamine in a paracrine fashion [38]. So the urinary
excretion of dopamine reflects the renal production of the
amine. The dopamine receptors in the kidney are D1 and
D2 types in brush-border and basolateral membranes of
proximal tubules and can alter blood flow and sodium
excretion [39]. With regard to differences between SHR
and WKY males, SHR males excretes more dopamine and
NE than WKY males across varying sodium intakes [40]
Representative kidney sections (6 μ) stained with H&E to  show glomeruli and tubules in: non-electroporated controls,  Sry1 electroporated, and control vector electroporated ani- mals Figure 6
Representative kidney sections (6 μ) stained with 
H&E to show glomeruli and tubules in: non-electro-
porated controls, Sry1 electroporated, and control 
vector electroporated animals.
Electroporated
Sry1
Electroporated
Control Vector
Normal 
ControlBMC Physiology 2009, 9:10 http://www.biomedcentral.com/1472-6793/9/10
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even though the dopamine receptor density is not differ-
ent [41]. If the Y chromosome and Sry were involved with
this mechanism, we would expect to see potentially more
urinary dopamine excreted in the Sry1 animals. Indeed,
after 7 days there was almost a doubling of urinary
dopamine in Sry1 animals compared to vector controls.
Consequently urinary sodium excretion may have been
expected to increase due to a dopamine natriuretic effect
but there was no difference in sodium excretion at 7, 14 or
21 days. There is a strong possibility that the elevated SNS
activity reflected as increased plasma and urinary NE
throughout this period, may have normalized the sodium
excretion. It has been shown that increased renal SNS
activity increases renin secretion rate and decreases uri-
nary sodium excretion [26]. The dopamine blockade
experiment suggested that even though there was no dif-
ference in sodium excretion at 7 days with no blocker,
when the dopamine blocker was given at 14 days the Sry1
animals did not respond with a significant decrease in
sodium excretion as expected, whereas the vector controls
had a significant 34% decrease. We do not know at this
time if Sry delivery altered dopamine receptor density or
if that the initial effect on dopamine (83% elevation) was
so large that the dopamine blocker was not enough to
reduce the sodium excretion to values seen in the vector
controls.
Other potential mechanisms that could elevate BP in
response to Sry1 are some of the hormones involved in BP
regulation. The lack of plasma renin activity difference
between Sry1 and control vector, imply that Sry1 is not
acting via the circulating renin angiotensin system (RAS),
but does not eliminate effects of the renal RAS. In addi-
tion, analysis of plasma aldosterone showed no signifi-
cant differences between controls and Sry1, suggesting
that sodium retention via aldosterone regulation is not a
key player in the noted BP increase. As with plasma renin
and aldosterone, plasma corticosterone showed no signif-
icant differences between controls and Sry1 animals for
each time period sampled, further indicating that
increased basal corticosterone is not responsible for the
BP differences. It was curious, however, that both aldos-
terone and corticosterone levels were elevated at the
beginning of the study (baseline and 7 days) and contin-
ued to decrease toward more normal levels with time. This
possibly may be due to a stress effect of getting use to the
blood collection procedure. Therefore, the similarities in
these hormone profiles between Sry1 and control vector
males indicate that the increased BP following renal trans-
fection of Sry1 is not via modulation of circulating renin,
aldosterone, or corticosterone.
Conclusion
Our results support the hypothesis that Sry1 but not Sry2
from the SHR male increases kidney Th, and elevated SNS
markers and increased peripheral vasoconstriction result-
ing in increased BP in a WKY normotensive animal. The
findings presented here confirm and extend the argument
for Sry1 as at least one of the genes responsible for the
hypertensive Y chromosome phenotype. These results are
consistent with an increased SNS activity mechanism, but
does not preclude Sry effects on other important blood
pressure regulation systems like the tissue renin angi-
otensin system. Sry1 is the first Y chromosome locus to
have hypertensive potential confirmed; however, this
result is not sufficient to conclude that Sry1 is solely or
directly responsible for the hypertensive effect of the SHR
Y chromosome, however not all Sry loci raise BP as seen
by the lack of a BP effect with the electroporation of Sry2
to the kidney. The Sry1 sequence and expression need to
be compared from normotensive and hypertensive Y
chromosomes and differences consistent with the electro-
poration results demonstrated to conclusively show that
Sry1 is responsible.
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